Applied BioCode Corporation (6598.TW)

TWD 19.05

(-0.52%)

Operating Income Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual operating income in 2023 was -186.7 Million TWD , down -2.63% from previous year.
Applied BioCode Corporation's latest quarterly operating income in 2024 Q2 was -55.8 Million TWD , up 19.4% from previous quarter.
Applied BioCode Corporation reported an annual operating income of -181.92 Million TWD in 2022, down -12.09% from previous year.
Applied BioCode Corporation reported an annual operating income of -162.3 Million TWD in 2021, down -63.68% from previous year.
Applied BioCode Corporation reported a quarterly operating income of -69.23 Million TWD for 2024 Q1, down -358.84% from previous quarter.
Applied BioCode Corporation reported a quarterly operating income of -15.09 Million TWD for 2023 Q4, up 64.89% from previous quarter.

Annual Operating Income Chart of Applied BioCode Corporation (2023 - 2013)

Historical Annual Operating Income of Applied BioCode Corporation (2023 - 2013)

Year	Operating Income	Operating Income Growth
2023	-186.7 Million TWD	-2.63%
2022	-181.92 Million TWD	-12.09%
2021	-162.3 Million TWD	-63.68%
2020	-99.15 Million TWD	63.74%
2019	-273.46 Million TWD	-2.18%
2018	-267.62 Million TWD	-1.43%
2017	-263.84 Million TWD	-35.61%
2016	-194.56 Million TWD	12.11%
2015	-221.37 Million TWD	-35.98%
2014	-162.79 Million TWD	-95.29%
2013	-83.35 Million TWD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-55.8 Million TWD	19.4%
2024 Q1	-69.23 Million TWD	-358.84%
2023 Q4	-15.09 Million TWD	64.89%
2023 FY	-186.7 Million TWD	-2.63%
2023 Q1	-49.41 Million TWD	-43.07%
2023 Q2	-60.49 Million TWD	-22.43%
2023 Q3	-42.98 Million TWD	28.95%
2022 FY	-181.92 Million TWD	-12.09%
2022 Q1	-73.12 Million TWD	-195.73%
2022 Q4	-34.54 Million TWD	20.26%
2022 Q3	-43.31 Million TWD	-40.0%
2022 Q2	-30.94 Million TWD	57.69%
2021 Q4	-24.72 Million TWD	59.07%
2021 Q2	-54 Million TWD	-133.23%
2021 Q1	-23.15 Million TWD	-147.93%
2021 FY	-162.3 Million TWD	-63.68%
2021 Q3	-60.41 Million TWD	-11.88%
2020 FY	-99.15 Million TWD	63.74%
2020 Q4	48.3 Million TWD	317.52%
2020 Q3	-22.2 Million TWD	72.9%
2020 Q2	-81.96 Million TWD	-89.3%
2020 Q1	-43.29 Million TWD	21.11%
2019 Q3	-67.26 Million TWD	12.15%
2019 FY	-273.46 Million TWD	-2.18%
2019 Q1	-74.74 Million TWD	-10.62%
2019 Q2	-76.57 Million TWD	-2.44%
2019 Q4	-54.87 Million TWD	18.41%
2018 Q2	-61.22 Million TWD	0.0%
2018 FY	-267.62 Million TWD	-1.43%
2018 Q4	-67.57 Million TWD	12.86%
2018 Q3	-77.53 Million TWD	-26.64%
2018 Q1	-61.22 Million TWD	-1.0%
2017 Q3	-60.62 Million TWD	14.98%
2017 Q2	-71.3 Million TWD	0.0%
2017 Q4	-60.62 Million TWD	0.0%
2017 Q1	-71.3 Million TWD	0.0%
2017 FY	-263.84 Million TWD	-35.61%
2016 Q4	- TWD	0.0%
2016 Q2	-47.81 Million TWD	0.0%
2016 FY	-194.56 Million TWD	12.11%
2015 FY	-221.37 Million TWD	-35.98%
2015 Q4	- TWD	0.0%
2014 FY	-162.79 Million TWD	-95.29%
2013 FY	-83.35 Million TWD	0.0%

Peer Operating Income Comparison of Applied BioCode Corporation

Name	Operating Income	Operating Income Difference
Excelsior Medical Co., Ltd.	702.88 Million TWD	126.562%
Apex Medical Corp.	194.21 Million TWD	196.13%
OK Biotech Co., Ltd.	-12.06 Million TWD	-1447.853%